Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169


Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.

Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA.

J Infect Dis. 2014 Apr 15;209(8):1156-64. doi: 10.1093/infdis/jiu012. Epub 2014 Jan 9.


Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.

Erlandson KM, Jiang Y, Debanne SM, McComsey GA.

AIDS. 2015 Jan 14;29(2):175-82. doi: 10.1097/QAD.0000000000000526.


Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.

Longenecker CT, Hileman CO, Funderburg NT, McComsey GA.

Clin Infect Dis. 2014 Oct 15;59(8):1148-56. doi: 10.1093/cid/ciu523. Epub 2014 Jul 11.


Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.

Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, Clagett B, Robinson J, Lederman MM, McComsey GA.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):396-404. doi: 10.1097/QAI.0000000000000478.


Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.

Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, Robinson J, Lederman MM, McComsey GA.

Clin Infect Dis. 2014 Feb;58(4):588-95. doi: 10.1093/cid/cit748. Epub 2013 Nov 18.


Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.

Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A.

Eur J Clin Invest. 2013 Jul;43(7):698-707. doi: 10.1111/eci.12095. Epub 2013 Apr 20.


Prevention of atherosclerosis in patients living with HIV.

De Lorenzo F, Boffito M, Collot-Teixeira S, Gazzard B, McGregor JL, Shotliff K, Xiao H.

Vasc Health Risk Manag. 2009;5(1):287-300. Epub 2009 Apr 8.


Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Ross Eckard A, Longenecker CT, Jiang Y, Debanne SM, Labbato D, Storer N, McComsey GA.

HIV Med. 2014 Oct;15(9):537-46. doi: 10.1111/hiv.12143. Epub 2014 Mar 20.


Will statins be an effective anti-inflammatory intervention for prevention of cardiovascular disease in patients with HIV?

Dubé MP.

J Infect Dis. 2014 Apr 15;209(8):1149-50. doi: 10.1093/infdis/jiu015. Epub 2014 Jan 9. No abstract available.


Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.

Dirajlal-Fargo S, Kinley B, Jiang Y, Longenecker CT, Hileman CO, Debanne S, McComsey GA.

AIDS. 2015 Jan 28;29(3):313-21. doi: 10.1097/QAD.0000000000000547.


Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.

Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS.

Atherosclerosis. 2013 Nov;231(1):8-14. doi: 10.1016/j.atherosclerosis.2013.08.013. Epub 2013 Aug 27.


Effect of rosuvastatin on plasma coenzyme Q10 in HIV-infected individuals on antiretroviral therapy.

Morrison JT, Longenecker CT, Mittelsteadt A, Jiang Y, Debanne SM, McComsey GA.

HIV Clin Trials. 2016 Jul;17(4):140-6. doi: 10.1080/15284336.2016.1184863. Epub 2016 Jun 13.


A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.

Talavera JO, Martinez G, Cervantes JL, Marin JA, Rodriguez-Briones I, Gonzalez JG, Ocampo R, Sanchez-Mijangos H, Bernal-Rosales LP, Polanco A.

Curr Med Res Opin. 2013 Apr;29(4):379-86. doi: 10.1185/03007995.2013.766590. Epub 2013 Feb 21.


Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients.

Calza L, Vanino E, Salvadori C, Manfredi R, Colangeli V, Cascavilla A, Di Bari MA, Motta R, Viale P.

HIV Clin Trials. 2014 Jan-Feb;15(1):1-13. doi: 10.1310/hct1501-1.


High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.

Mora S, Glynn RJ, Ridker PM.

Circulation. 2013 Sep 10;128(11):1189-97. doi: 10.1161/CIRCULATIONAHA.113.002671. Epub 2013 Sep 3.


Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.

Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, Koyama T, Iino K, Kosaka T, Ito H.

Lipids Health Dis. 2013 Feb 4;12:9. doi: 10.1186/1476-511X-12-9.


Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.

Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD.

Arterioscler Thromb Vasc Biol. 2007 Oct;27(10):2236-43. Epub 2007 Jul 26.

Supplemental Content

Support Center